Despite the still critical limitations from an incomplete understanding of disease mechanisms, a lack of reliable clinical biomarkers, variable drug effects on less-then optimal mouse models, and limited implementation of humanized cellular models of tauopathy, the field has seen groundbreaking advances in multiple fronts for development of tau therapeutics [299,300]. The gene discussed is MAPT; the disease is tauopathy.